Empagliflozin in Type 2 Diabetes Mellitus Patients with High Cardiovascular Risk: A Model-Based Cost-Utility Analysis in China

Código QR

Empagliflozin in Type 2 Diabetes Mellitus Patients with High Cardiovascular Risk: A Model-Based Cost-Utility Analysis in China

Peng Men,1,2 Tianbi Liu,1,3 Suodi Zhai1,2 1Department of Pharmacy, Peking University Third Hospital, Beijing, People’s Republic of China; 2Institute for Drug Evaluation, Peking University Health Science Center, Beijing, People’s Republic of China; 3Department of Pharmacy Administ...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Men P, Liu T, Zhai S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	diabetes china sodium-glucose transporter 2 inhibitors cost-effectiveness Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/6daeb1e86f94447fb0247f4365e0414e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin
por: Avgerinos I, et al.
Publicado: (2019)

Comparison of the changes in the factors associated with the renal prognosis of non-elderly and elderly subjects treated with empagliflozin- a retrospective observation study in Japanese patients with type 2 diabetes
por: Ito H, et al.
Publicado: (2019)

Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence
por: Bonora BM, et al.
Publicado: (2020)

Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome
por: Davies MJ, et al.
Publicado: (2017)

Empagliflozin in type 1 diabetes
por: Mathieu C, et al.
Publicado: (2019)

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
por: Santos Cavaiola T, et al.
Publicado: (2018)

Experiencia de uso de inhibidores del cotransportador sodio-glucosa 2 en diabéticos tipo 2
por: Contreras,Álvaro, et al.
Publicado: (2019)

The Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Advanced-Stage Diabetic Kidney Disease Taking Renin-Angiotensin System Blockers
por: Hirai K, et al.
Publicado: (2020)

Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes
por: Papakitsou I, et al.
Publicado: (2019)

Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice
por: Nguyen T, et al.
Publicado: (2020)

Empagliflozin Ammeliorates High Glucose Induced-Cardiac Dysfuntion in Human iPSC-Derived Cardiomyocytes
por: Kwong-Man Ng, et al.
Publicado: (2018)

Identification of Significant Predictors for the Need of Insulin Therapy and Onset of Postpartum Impaired Glucose Tolerance in Gestational Diabetes Mellitus Patients
por: Wang T, et al.
Publicado: (2021)

Adjunctive therapy for glucose control in patients with type 1 diabetes
por: Harris K, et al.
Publicado: (2018)

Empagliflozin Protects Against Proximal Renal Tubular Cell Injury Induced by High Glucose via Regulation of Hypoxia-Inducible Factor 1-Alpha
por: Ndibalema AR, et al.
Publicado: (2020)

The Factors Influencing the Renal Glucose Threshold in Patients with Newly Diagnosed Type 2 Diabetes Mellitus
por: Cui SS, et al.
Publicado: (2021)

Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors
por: Fan Yang, et al.
Publicado: (2020)

Relationship Between the TyG Index and Diabetic Kidney Disease in Patients with Type-2 Diabetes Mellitus
por: Lv L, et al.
Publicado: (2021)

Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes
por: Munir KM, et al.
Publicado: (2016)

Mechanisms of cardiovascular protection of non-insulin antidiabetic medications
por: Angelo Avogaro
Publicado: (2018)

Predictors of Insulin Treatment During Pregnancy and Abnormal Postpartum Glucose Metabolism in Patients with Gestational Diabetes Mellitus
por: Tang L, et al.
Publicado: (2019)

The Impact of the One-Day Clinic Diabetes Mellitus Management Model on Perinatal Outcomes in Patients with Gestational Diabetes Mellitus
por: Cao YM, et al.
Publicado: (2021)

Combination of Metformin and Exercise in Management of Metabolic Abnormalities Observed in Type 2 Diabetes Mellitus
por: Jevtovic F
Publicado: (2021)

Type 2 diabetes in Vietnam: a cross-sectional, prevalence-based cost-of-illness study
por: Le NTD, et al.
Publicado: (2017)

Prolonged ketosis and glycosuria secondary to SGLT2 inhibitor therapy
por: David Bobrowski, et al.
Publicado: (2021)

Effects of coenzyme Q10 on cardiovascular and metabolic biomarkers in overweight and obese patients with type 2 diabetes mellitus: a pooled analysis
por: Huang H, et al.
Publicado: (2018)

Incidence and Intensity of Catastrophic Health-care Expenditure for Type 2 Diabetes Mellitus Care in Iran: Determinants and Inequality
por: Piroozi B, et al.
Publicado: (2020)

Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus
por: Kushner P
Publicado: (2010)

Critical appraisal of the safety and efficacy of insulin detemir in glycemic control and cardiovascular risk management in diabetics
por: Le Floch J
Publicado: (2010)

Profile of Overweight and Obesity in Children and Adolescents and Frequency of Type 2 Diabetes Mellitus and Glucose Intolerance: A Study in Public School in Brazil
por: Zaccarelli-Marino MA, et al.
Publicado: (2020)

Role of sodium glucose cotransporter-2 inhibitors in type I diabetes mellitus
por: Ahmadieh H, et al.
Publicado: (2017)

Teneligliptin real-world efficacy assessment of type 2 diabetes mellitus patients in India (TREAT-INDIA study)
por: Ghosh S, et al.
Publicado: (2016)

Association of Glycated Albumin/Glycosylated Hemoglobin Ratio with Blood Glucose Fluctuation and Long-Term Blood Glucose Control in Patients with Type 2 Diabetes Mellitus
por: Wang BR, et al.
Publicado: (2021)

Safety and effectiveness of ipragliflozin in Japanese patients with type 2 diabetes mellitus and impaired renal function: subgroup analysis of a 3-year post-marketing surveillance study (STELLA-LONG TERM)
por: K. Tobe, et al.
Publicado: (2021)

Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies
por: Schwartz S
Publicado: (2010)

Physical Exercise is Associated with Glycemic Control among Women with Gestational Diabetes Mellitus: Findings from a Prospective Cohort in Shanghai, China
por: Wang R, et al.
Publicado: (2021)

SGLT2 inhibitors and kidneys: mechanisms and main effects in diabetes mellitus patients
por: Vladimir V Salukhov, et al.
Publicado: (2021)

Diabetes Mellitus and Its Associated Factors in Tuberculosis Patients in Maekel Region, Eritrea: Analytical Cross-Sectional Study
por: Araia ZZ, et al.
Publicado: (2021)

Chronic oscillating glucose challenges disarrange innate immune homeostasis to potentiate the variation of neutrophil–lymphocyte ratio in rats with or without hidden diabetes mellitus
por: Yang G, et al.
Publicado: (2018)

Cost of Diabetic Foot Ulcer Management in China: A 7-Year Single-Center Retrospective Review
por: Lu Q, et al.
Publicado: (2020)

Hematological indices and their correlation with fasting blood glucose level and anthropometric measurements in type 2 diabetes mellitus patients in Gondar, Northwest Ethiopia
por: Biadgo B, et al.
Publicado: (2016)